CN102018701B - Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors - Google Patents
Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors Download PDFInfo
- Publication number
- CN102018701B CN102018701B CN2010105218283A CN201010521828A CN102018701B CN 102018701 B CN102018701 B CN 102018701B CN 2010105218283 A CN2010105218283 A CN 2010105218283A CN 201010521828 A CN201010521828 A CN 201010521828A CN 102018701 B CN102018701 B CN 102018701B
- Authority
- CN
- China
- Prior art keywords
- glucosidase
- alpha
- lignans
- flavonol
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention relates to application of angle flavonol lignans to preparing glucosidase inhibitors, in particular to application of B-ring dioxane angle flavonol lignans or pharmaceutically acceptable salts thereof to preparing drugs for inhibiting alpha-glucosidase and preventing and treating type II diabetes mellitus. The flavonol lignans have extremely obvious activity for inhibiting alpha-glucosidase and the intensity of activity of the flavonol lignans for inhibiting alpha-glucosidase has reached 66.7% at the concentration of 40mcg/ml. The measured half-inhibitory concentration of the flavonol lignans shows that the intensity of activity of the flavonol lignans for inhibiting alpha-glucosidase is 4.4 times that of the positive control drug acarbose. The pharmacodynamics result shows that the flavonol lignans or pharmaceutically acceptable salts thereof can be expected to be applied to preparing glucosidase inhibitors, especially the drugs for preventing and treating type II diabetes mellitus, namely non-insulin dependent diabetes mellitus.
Description
Technical field
The present invention relates to medical technical field; Particularly; Angle type flavanolignan or its officinal salt that the present invention relates to a kind of B epidioxy six rings is used for preparing the inhibition alpha-glucosidase, the control type ii diabetes also is the purposes of non-insulin-dependent diabetes mellitus medicine; This flavanolignan has the activity that suppresses alpha-glucosidase extremely significantly; Its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 66.7%; Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 4.4 times of positive control medicine acarbose; Therefore this chemical compound or its pharmaceutically useful salt, and the pharmaceutical composition that becomes with preparation allowable pharmaceutical excipients or preparing carriers can be expected and especially prevented and treated the purposes that type ii diabetes also is the non-insulin-dependent diabetes mellitus medicine as glycosidase inhibitor.
Background technology
Along with scientific and technological progress and growth in the living standard, in the world, the sickness rate of diabetes improves.According to statistics, diabetes occur on about 3% the person, and whole world patient's total number of persons surpasses 100,012,000, causes the heavy losses of national economy.
Diabetes are clinical common endocrine metabolism property diseases.Doctor trained in Western medicine thinks that diabetic can be divided into two kinds: promptly (or claim insulin-dependent, IDDM) (or title non-insulin-depending type, NIDDM), wherein type ii diabetes is wider, endangers bigger with type ii diabetes for type i diabetes.China's diabetics has more than 2,000 ten thousand, and wherein nearly 90% is type ii diabetes.Along with the change of life style, dietary habit, and the development of science and technology and medical level, detecting factors such as the early diabetes level improves constantly, countries in the world life expectancy and onset diabetes rate are all improving constantly.This disease characteristics multiple, rejuvenation occurred especially in China, has caused very large loss for the national economy and productivity development.
The oral drugs of treatment type ii diabetes have sulfonylurea, biguanides, alpha-glucosidase inhibitor class and insulin sensitizer four big kinds at present, but each tool pluses and minuses.Alpha-glucosidase inhibitor is the research and development theory of the new treatment NIDDM that begins to rise the seventies in last century.This is the supplement therapy means of the invalid type ii diabetes of treatment sulfa drugs secondary.Bibliographical information uses competitive alpha-glucosidase inhibitor, can postpone conversion and the absorptions of saccharide compound in digestive tract such as starch, sucrose, alleviates the kidney burden; Suppress after meal that blood glucose sharply rises, make blood sugar concentration in one day, change fluctuating margin and reduce.This is Fructus Vitis viniferae IGR impaired glucose tolerance (IGT) stage especially of effectively suppressing diabetics early stage, many as yet not the potential patients of diabetes of morbidity still be in the middle of this stage.The Alpha-glucosidase inhibitor acarbose (acarbose) of Bayer A.G's development went on the market in Germany in nineteen ninety, had become a plurality of countries at present, comprised China, a line medication of treatment type ii diabetes, and its commodity are called acarbose.Type ii diabetes research in policy group in the Asian-Pacific area provided the treatment guide in 2005, and (inhibitor of α-glucosidase) is as the first-selected medication that reduces post-prandial glycemia with alpha-Glucosidase.Various countries launch keen competition to new Alpha-glucosidase inhibitor and hypoglycemic medicine.The alpha-glucosidase inhibitor voglibose (voglibose) of Japan's exploitation is also in listing in 1994.Yet it occupies the competition that high price will receive the similar medicine of novel cheap novelty.Just the alpha-glucosidase inhibitor in clinical trial also has miglitol (miglitol), emigliate etc.It should be noted that: the untoward reaction of the increasing alpha-glucosidase inhibitor that gone on the market also claims to the new inhibitor that updates.Skin allergies such as gastrointestinal side effect, erythema, erythra and urticaria; The severe hepatic dysfunction of jaundice, GOT, GPT rising etc.; Cardiac system risk etc. all be such the treatment blind area of marketed drug [referring to Li Zhongfen, " adverse effect journal the 4th phase of calendar year 2001; Yang Xiaohui etc., " Chinese pharmacovigilance " 1 phase in 2009; Deng bibliographical information].Thereby develop actively is imitated more by force, the novel abiotic bases Alpha-glucosidase inhibitor of safety has urgency and necessity.
Based on this purpose; The inventor once accomplished the research of multinomial development of new alpha-glucosidase inhibitor class natural product and structure of modification derivant thereof; And find the chemical compound of multiple inhibition alpha-glucosidase activity; Thereby explain that it is feasible [referring to " application of arjunolic acid in the preparation glycosidase inhibitor " from natural product and synthesis of derivatives thereof, filtering out novelty hypoglycemic medicine that strong effect suppresses alpha-glucosidase inhibitor; Zhang Rongping, Dou Hui, Zhao Yu, Wu Xiumei etc., CN 101416970; " application of belulinic acid Betulinic acid in the preparation glycosidase inhibitor ", Zheng Hanqi, Dou Hui, Zhang Rongping, Zhao Yu, Wu Xiumei etc., CN 101416971; " the substituted ramification of pentacycle triterpene of A ring polyoxyization ", Zhao Yu, Feng Juhong, Wu Xiumei, Bai Hua, the uncommon spy of Yue Ashi Stoker, CN 101117349; " the substituted pentacyclic triterpene of A ring and C ring both polyoxyization ", Zhao Yu, Chen Haiyong, Zheng Hanqi, Wu Xiumei, Bai Hua, the uncommon spy of Yue Ashi Stoker, CN 101117348].Undoubtedly, it is very necessary and urgent continuing from natural product and structure of modification derivant thereof, to seek the lead compound that can suppress alpha-Glucosidase.
In addition, protecting the liver in the kind new medicine exploitation problem of inventor's long-term accumulation, a large amount of clinically a kind of natural drugs that use have been related to: promptly be present in the silymarin in the seed of feverfew Herba Silybi mariani.Herba Silybi mariani is extensive use clinically, its commodity Legalon by name on market
TMGrand or the Flavobion of sharp liver
TM, its representative compound surely belongs to flavanolignan's silibinin.Flavone lignin compound belongs to weedtree quality class, is one type of natural product of and a part flavone be combined into plain by a part phenylpropyl alcohol.Silibinin content is maximum in the Herba Silybi mariani, and activity is also the highest.This medicine effect mainly contain following some: (one) free radical resisting is active: silymarin has protective effect for the hepatic injury that is caused by carbon tetrachloride, galactosamine, alcohols and other hepatotoxin.People such as nineteen ninety Lotteron have reported in the Mouse Liver microsome; Silymarin can reduce external lipid peroxidation that is caused by the carbon tetrachloride metabolism and the peroxidation that is caused separately by reduced coenzyme, and these show that all silymarin is the chain interruption antioxidant or is free radical scavenger.(2) protection liver plasma membrane: keep flowability of cell membranes through the anti peroxidation of lipid reaction, the protection liver plasma membrane.Can also block combining of special receptor on mycotoxin phalloidine and α-amanitin etc. and the hepatocyte, suppress it, interrupt its liver sausage circulation, thereby the enhance hepatocyte film be for the resistance of multiple damage factor hepatocellular attack and transmembrane transport.(3) promote hepatocellular reparation and regeneration: silibinin can combine with ER after getting into cell; And make it to activate; Activated receptors can enhance hepatocyte nuclear RNA polymerase 1 activity, rna transcription is strengthened, promote enzyme and proteinic synthetic; And promote the synthetic of DNA indirectly, help hepatocellular reparation and regeneration.(4) antitumor action: various active oxygens can form 8-hydroxyl guanine by the oxidation guanine, cause DNA damage, and then cause tumor, and silibinin has also shown the effect of prevention and treatment tumor as an effective free radical resisting material.This medical instrument of the clinical trial certificate of three more than ten years has definite curative effect and hypotoxicity (to consult Flora K. etc., Am.J.Gastroenterol, 1998,93,139-143; SallerR. etc., Drugs, 2001,61 (14), 2035-2063;
R. etc.; Curr.Med.Chem.; 2007; 14,315-338;
Z. etc.; Phytother.Res.; 2003; 17,524-530;
R. etc.; Bioorg.Med.Chem.; 2004; 12,5677-5687; Varga Z. etc., Phytothe.Res., 2001,15,608-612; Singh R.P. etc., Curr.CancerDrug Tar., 2004,4,1-11).Therefore; The flavone lignin chemical compound that with the silibinin is representative has caused increasing concern; In the period of 2006-2009, prepare and a plurality of serial silibinin analog derivative reported also has obvious antioxidation activity (Yang Leixiang, Zhao Yu etc., " Design, synthesis and examination of neuron protectiveproperties of alkenylated and amidated dehydro-silybin derivatives " like the inventor; Journal of Medicinal Chemistry; 2009,52 (23), 7732-7752; Wang Feng, Zhao Yu etc.; " Preparation of C-23 esterified silybin derivatives and evaluation oftheir lipid peroxidation inhibitory and DNA protective properties "; Bioorganic and Medicinal Chemistry; 2009,17 (17), 6380-6389; Yang Leixiang, Zhao Yu etc.; " Synthesis and antioxidant properties evaluation of novelsilybin analogues ", Journal of Enzyme Inhibition and MedicinalChemistry, 2006; 21 (4), 399-404; Or the like).In the above-mentioned article of inventor report, A ring, B ring, E ring and 23 substituted flavanolignan compounds of a plurality of series that design and synthesize out through the inventor all demonstrate strong effect and catch the activity of DPPH free radical and ultra-oxygen anion free radical, antioxidant activity and protection PC12 cell activity.But obvious: above-mentioned research only concentrates on antioxidation and the cytoprotection of studying the silibinin flavonolignan.
Though with silibinin and dehydro-silibinin is that flavanolignan's chemical compound of representative has the antioxidation curative effect of the above, yet do not see that it is used to suppress the report of glycosidase, treatment diabetes aspect.Flavanolignan's compounds for treating type ii diabetes; Especially its new purposes that is used to suppress alpha-glucosidase is effectively developed as yet; So from flavanolignan, seek to suppress the reactive compound of alpha-glucosidase, also being about to flavanolignan's structure of modification, to make it have treatment type ii diabetes effect be a brand-new field.From wherein finding the efficient lead compound challenge that forefathers did not attempt especially that suppresses alpha-glucosidase.In order to explore this field; Our design has also prepared and the silibinin structure a kind of new angle type flavanolignan derivant of difference to some extent, also promptly is coupled to dioxane at B ring prosposition; Form C ring/B ring/D ring and be upset angie type ring system space structure; And silibinin is because of on the B ring being the synthetic dioxane modes of 3,4 digit pairs, so its C ring/B ring/D ring is linear stretch ring system space structure.So design can generate the plain flavanone alcohol compound (also being one type of novel flavanolignan chemical compound) of one type of novel wooden that the new spatial structure is different from silibinin fully; In the hope of finding to suppress flavanolignan's lead compound of alpha-glucosidase, has the novelty medicine that can suppress alpha-glucosaccharase enzyme treatment NIDDM thereby it is developed further into.Accomplish the present invention in view of the above.
Summary of the invention
The angle type flavanolignan or its officinal salt that the purpose of this invention is to provide B epidioxy six rings of structure shown in the formula (1) are used for the purposes that preparation suppresses alpha-glucosidase, treatment NIDDM disease medicament;
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(4-hydroxy phenyl)-2-methylol-1,4 benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
The present invention also provides the method for the angle type flavanolignan chemical compound of B epidioxy six rings shown in a kind of preparation formula (1); It is characterized in that: (±)-2-(2; The 3-dihydroxy phenyl)-2,3-dihydro-3,5; 7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone and carries out coupling reaction to the hydroxyl cinnamyl alcohol and gets under silver catalyst;
Wherein silver salt is meant Disilver carbonate, silver oxide or silver nitrate, and embodiment has adopted Disilver carbonate among the present invention; Anhydrous reagent is meant anhydrous aprotic solvent or their a certain proportion of mixture such as anhydrous benzene, anhydrous propanone, anhydrous tetrahydro furan, and embodiment has adopted the mixed solvent of anhydrous benzene and anhydrous propanone among the present invention.
Another object of the present invention has provided a kind of pharmaceutical composition that is used to suppress alpha-glucosidase, treatment NIDDM disease, it is characterized by the perhaps mixture formed of its officinal salt and pharmaceutically acceptable auxiliaries of the formula as active component (1) chemical compound of treat effective dose by containing.Its pharmaceutical dosage form can be that tablet, capsule, injection, aerosol, suppository, membrane, drop pill, paster agent, subcutaneous planting bury agent, externally-applied liniment, oral liquid or ointment, can also adopt the known controlled release of modern pharmaceutical circle or slow release formulation or nanometer formulation.
Description of drawings the structural difference of angle type flavanolignan and silibinin class linear stretch flavanolignan in the design concept of the present invention, promptly the C/B/D ring system of silibinin is the linear stretch direction, and the C/B/D ring system of chemical compound (1) is angle type direction of extension.
The angle type flavanolignan (1) of B epidioxy six rings of inventor's design compares with natural flavone Lignanoids compounds silibinin; Characteristic with differentiation on many structures and the physico-chemical property comprises that speciality such as its hydrophobicity, armaticity, Gibbs free energy, hydrogen bond receptor, electrical, intermolecular Van der Waals force and 3D conformation, direction of extension, molecule center of gravity, electrical distribution center all have obviously different with silibinin; And chemical compound (1) molecular weight ratio silibinin has reduced 30 mass units.The ligand-receptor that above-mentioned characteristic has all determined the three-dimensional conformation of chemical compound shown in the formula (1) to combine with the 3d space structure of alpha-glucosidase combines complex form and combination all possibly produce bigger difference; Its binding site and binding pattern, its combination free energy etc. all can produce bigger change, thereby possibly suppress aspect the alpha-glucosidase beyond thought effect arranged.
We have tested the growth inhibited effect of this chemical compound to alpha-glucosidase; Result of the test is found: this flavanolignan has the activity that suppresses alpha-glucosidase extremely significantly; Its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 66.7%; Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 4.4 times of positive control medicine acarbose; Above pharmacodynamic result explanation formula (1) chemical compound has beyond thought inhibition alpha-glucosidase effect, thereby can expect that this flavanolignan or its officinal salt can be expected especially prevents and treats the purposes that type ii diabetes also is the non-insulin-dependent diabetes mellitus medicine as glycosidase inhibitor.
In sum; Uniqueness on this flavanolignan's existing structure that we prepare; The novelty that suppresses glycosidase effect aspect research is arranged again; And in hypoglycemic activity test, found the activity of uncommon inhibition alpha-glucosidase to be expected to become the lead compound that suppresses alpha-glucosidase and treatment NIDDM.Up to the present, still there is not the relevant report that suppresses the alpha-glucosidase medicine about this compounds for treating NIDDM disease and preparation.Flavanolignan's formula (1) chemical compound is imitated by force for alpha-glucosidase and is suppressed to belong to beyond thought discovery, and definite originality is arranged.
Usefulness of the present invention is: the flavanonol lignanoid of six rings of the B epidioxy shown in the discoverable type (1) has the effect of extremely strong effect inhibition alpha-glucosidase and has the patent medicine potentiality aspect the control NIDDM disease first, and the innovative hypoglycemic medicine that becomes treatment NIDDM disease original new drug, exploitation inhibition alpha-glucosidase for exploitation provides new material base.Have potential huge social benefit and economic benefit.The present invention's characteristics again is: the present invention's synthetic starting material convenient sources, and its preparation method is simple, and cost is low, pollutes for a short time, is beneficial to the large-scale production under the energy-saving and emission-reduction condition.Industrialization prospect is very clear and definite.
The specific embodiment
The inventor is simply synthetic through multistep, and obtains flavanolignan's class reactive compound that this can effectively suppress alpha-glucosidase activity through the chromatography means, derives its chemical constitution through integration analysis such as mass spectrum and NMR spectrums again.The inventor finds that formula (1) chemical compound has significant inhibitory effect to alpha-glucosidase.Therefore; According to the inventor's research, the inventor design and synthetic formula (1) shown in the flavanonol lignan compound of B epidioxy six ring can be used to prepare the medicine that suppresses alpha-glucosidase, control NIDDM disease and be used to treat type ii diabetes.
In order to understand essence of the present invention better, use the preparation of formula (1) chemical compound and the result that the inhibitory action of alpha-glucosidase is tested thereof below respectively, its new purposes in pharmaceutical field is described.Embodiment has provided partial synthesis, the structure of formula (1) chemical compound and has identified and activity data.Wherein OM is meant methoxyl group, and OMOM is meant the methoxy methoxy base.Mandatory declaration, embodiments of the invention are to be used to explain the present invention rather than limitation of the present invention.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the present invention and requires the scope protected.
Embodiment 1:Formula (1) (±)-2-[2,3-dihydro-3-(4-hydroxy phenyl)-2-methylol-1,4 benzodioxane-5]-2,3-dihydro-3,5, the apparatus for preparation and the reagent of 7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone:
Ultraviolet spectra is measured with Shimadzu UV-240 ultraviolet spectrophotometer; Proton nmr spectra
1H-NMR measures (tetramethylsilane ether TMS is interior mark) by INOVA type NMR spectrometer with superconducting magnet (VARIAN INOVA-400MHz); Electrospray Mass Spectrometry ESI-MS is measured by BrukerEsquire 3000+ mass spectrograph, and column chromatography is produced by Haiyang Chemical Plant, Qingdao with silica GF254 (10-40 order) with silica gel (100-200,200-300 and 300-400 order) and thin layer chromatography; Agents useful for same is analytical pure; Thin layer preparative chromatography (PTLC) is with the aluminium foil silica gel plate of Merck company; Column chromatography adopts Sweden Amersham Pharmacia Biotech AB Company products with polydextran gel Sephadex LH-20; Reverse phase silica gel RP-18 adopts the Chromatorex product of Japanese Fuii Silysia Chemical company; MCI is a Mitsubishi chemical company product, and thin plate (TLC) detects with 254 and the uviol lamp of 365nm; Developer is with iodine vapor, 10% sulphuric acid-ethanol and phosphorus molybdenum acid solution.
1.1 the preparation of starting material A:
2,3-4-dihydroxy benzaldehyde 4.8 grams are dissolved in 30 milliliters of acetone, stir to add potassium carbonate 17.5 grams after 10 minutes, drip 6 milliliters of chloromethyl ethers again, and reflux 1 hour is filtered, and filtrating concentrating obtains yellow oil 7.0 grams, directly is used for next step reaction.
1.2 the preparation of starting material B:
40 milliliters of DMF solution ice-water baths cooling with the sodium hydride of 2.6 grams; Dropwise 5 .6 gram 2,4 under the nitrogen protection state, 60 milliliters of benzene of 6-trihydroxy-acetophenone and the mixed solution of 7.0 milliliters of DMF; The ice bath cooling drips 9.0 milliliters of chloromethyl ether solution down, stirs 24 hours under the room temperature.In 100 milliliter of 10% sodium hydrate aqueous solution of impouring, ether extraction 3 times, each 50 milliliters; The saturated sodium bicarbonate washing, anhydrous sodium sulfate drying filters; Concentrate 40 gram 200-300 order silica gel column chromatographies, 4: 1 eluting of petroleum ether/ethyl acetate; Obtain 7.0 gram starting material B (2,4,6-trimethoxy methoxyacetophenone).Yellow oil; R
f(petroleum ether/ethyl acetate=3: 1): 0.30; Proton nmr spectra (400MHz, deuterochloroform): δ 2.52 (unimodal, 3H, CH
3), 3.50 (unimodal, 9H, OCH
3), 5.17 (unimodal, 6H, OCH
2O), 6.52 (unimodal, 2H, H-3,5).
1.3 the preparation of intermediate chalcone derivative:
2.8 the gram potassium hydroxide dissolves in 30 ml methanol, stirring drips down 10 milliliters of the mixing methanol solutions of 1.4 gram starting material A and 1.3 gram starting material B, stirs 8 hours under the room temperature; Remove solvent under reduced pressure, in residue, add 20 ml waters, ethyl acetate extraction (3 times; Each 20 milliliters), merge organic layer, remove solvent under reduced pressure after; Residue is through 30 gram 200-300 order silica gel column chromatographies, and 3: 1 eluting of petroleum ether/ethyl acetate obtain 1.76 gram intermediate chalcone derivative.Yellow oil; R
f(petroleum ether/ethyl acetate=2: 1): 0.38; UV: (methanol) λ max:209,300nm.Be used for next step reaction.
1.4 the preparation of intermediate epoxy chalcone derivative:
1.4 gram intermediate chalcone derivative is dissolved in 25 ml methanol, adds 1.6 milliliters of 2N potassium hydroxide aqueous solutions, adds 1.6 milliliter of 30% hydrogen peroxide solution again, stirring at room 2 hours.Add 25 ml waters, concentrating under reduced pressure is with ethyl acetate extraction (3 times; Each 20 milliliters), merge organic layer, anhydrous sodium sulfate drying; Filter, remove solvent under reduced pressure after, residue is through 20 gram 200-300 order silica gel column chromatographies; 3: 1 eluting of petroleum ether/ethyl acetate obtain 1.1 gram intermediate epoxy chalcone derivative.Yellow oil; R
f(petroleum ether/ethyl acetate=2: 1): 0.33; UV: (methanol) λ max:210,285nm.Be used for next step reaction.
1.5 important intermediate (±)-2-(2, the 3-dihydroxy phenyl) 2,3-dihydro-3,5, the preparation of 7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone:
1.0 gram intermediate epoxy chalcone derivative is dissolved in 15 ml methanol, adds under the stirring in the 10 ml methanol solution that are dissolved with 1.5 milliliters of concentrated hydrochloric acid, heats up 60 ℃ and reacts half an hour, removes heating; Remove solvent after the cooling under reduced pressure, in residue, add 50 ml waters, with ethyl acetate extraction (3 times, each 20 milliliters); Merge organic layer, saturated common salt washing 2 times, anhydrous sodium sulfate drying filters; After removing solvent under reduced pressure, residue is through 20 gram 200-300 order silica gel column chromatographies, and 3: 1 eluting of petroleum ether/ethyl acetate obtain 97 milligrams (±)-2-(2; The 3-dihydroxy phenyl) 2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.Yellow oil: R
f(chloroform/methanol=3: 1): 0.23; Electrospray Mass Spectrometry ESI-MS m/z:303 [M-H]
+
1.6 the preparation of chemical compound (1)
In exsiccant reaction bulb, drop into Disilver carbonate 0.22 gram; Add 20 milliliters of anhydrous benzene and 5 milliliters of anhydrous propanones, drip 90 milligrams (±)-2-(2, the 3-dihydroxy phenyl) 2 under the room temperature; 3-dihydro-3; 5,3 milliliters of the anhydrous propanone solution of 5 milliliters and the 76 milligrams 4-hydroxyl cinnamyl alcohol of anhydrous benzene solution of 7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone, insulation reaction is 12 hours in the time of 55 ℃.Leave standstill after being chilled to room temperature, the elimination insoluble matter, the mother solution concentrating under reduced pressure gets yellow oil, and warp 20 gram 200-300 order silica gel are column chromatography repeatedly, and 10: 1 eluting of chloroform/methanol through the gel filtration chromatography purification, finally obtain 18 milligrams of chemical compounds 1.R
f(chloroform/methanol/ethyl acetate/acetone/acetic acid=11: 0.5: 1: 1: 0.1): 0.15; Proton nmr spectra
1H NMR (400MHz, deuterated acetone) δ: 3.95 (multiplet, 1H, H-23a), 4.23 (multiplet, 1H, H-23b), 4.87 (bimodal, J=8.0Hz, 1H; H-11), 4.99 (bimodal, J=11.2Hz, 1H, H-3), 5.50 (multiplet, 1H, H-12), 5.67 (bimodal, J=11.2Hz; 1H, H-2), 5.84 (bimodal, J=1.2Hz, 1H, H-6), 5.87 (bimodal, J=1.2Hz, 1H, H-8); (6.69 bimodal, J=8.0Hz, 2H, H-19,21), 6.98 (multiplet, 1H, H-15), 7.02 (bimodal, J=8.0Hz; 1H, H-14), 7.11 (bimodal, J=8.0Hz, 1H, H-16), 7.22 (bimodal, J=8.0Hz, 2H, H-18; 22), 10.20 (wide unimodal, 1H, OH-20), 10.56 (wide unimodal, 1H, OH-7), 12.19 (unimodal, 1H, 5-OH); Electrospray Mass Spectrometry ESI-MS m/z:451 [M-H]
+
Embodiment 2: chemical compound (1) (±)-2-[2,3-dihydro-3-(4-hydroxy phenyl)-2-methylol-1,4 benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone detects the inhibition of alpha-glucosidase is active
2.1 instrument and reagent
2.1.1 experimental apparatus
ELIASA: ELISA plate reader (Bio-Tek Instruments, USA)
2.1.2 reagent
Alpha-glucosidase (α-D-glucosidase, Sigma, 500U/ milliliter); 4-nitrophenols-α-D-pyranglucoside (PNPG, Merck), reductive glutathione (worker is given birth in Shanghai), acarbose is acarbose (Bayer HealthCare Co, Beijing).
2.2 method of testing
Chemical compound is measured the inhibitory action of alpha-glucosidase and is adopted colorimetry.Add phosphate buffer (67 mMs/liter, pH 6.8,170 microlitres) in the sample well, reduced form glutathione (1 mg/ml; 5 microlitres), α-D-glucosidase (being diluted to the 0.2U/ milliliter with phosphate buffer, 25 microlitres), chemical compound (1) dissolves with dimethyl sulfoxine; With the phosphate buffer dilution, every hole 25 microlitres, making its final concentration is 0.04 mg/ml, 0.004 mg/ml; 0.0004 mg/ml adds substrate 4-nitrophenols-α-D-pyranglucoside (23.2 mMs/liter, 25 microlitres), 37 ℃ at last; Behind the water-bath 15 minutes, add sodium carbonate (1 mol, 50 microlitres) cessation reaction, in the colorimetric determination of 405nm wavelength.Tris-HCl buffer with equal volume in the blank well replaces substrate.Add and the isocyatic dimethyl sulfoxine of chemical compound in the solvent control hole.The chemical compound suppression ratio is calculated with contrast OD value for blank by sample OD value.Sample is to the half-inhibition concentration (IC of alpha-glucosidase
50) obtain by dose effect curve.
2.3 result of the test is as shown in the table
Table 1
2.4 experiment conclusion
Alpha-glucosidase be in the alpha-glucosidase inhibitor drug screening index property testing enzyme, many medicines are based on becomes hypoglycemic medicine to the alpha-glucosidase competitive inhibition.This experiment shows that the flavanonol lignanoid of B epidioxy six rings of structure shown in the formula (1) has the effect that strong effect suppresses alpha-glucosidase, and its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 66.7%.Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 4.4 times of positive control medicine acarbose; Thereby have very strong potentiality to be exploited of imitating, might further develop becomes new treatment type ii diabetes medication.
When above-mentioned description elaboration was of the present invention, the purpose that embodiment is provided simultaneously was to illustrate actual mechanical process of the present invention and meaning of the present invention.In the time of in getting into claim of the present invention and its equivalent scope, practical application of the present invention comprises all general variations, cooperates, or improves.
Claims (2)
1. the angle type flavanolignan or the purposes that its officinal salt is used to prepare the medicine of preventing and treating type ii diabetes that have B epidioxy six ring of structure shown in the formula (1);
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(4-hydroxy phenyl)-2-methylol-1,4 benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
2. the angle type flavanolignan or the application of its officinal salt in the hypoglycemic medicine of preparation inhibition alpha-glucosidase that have B epidioxy six rings of structure shown in the formula (1);
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(4-hydroxy phenyl)-2-methylol-1,4 benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105218283A CN102018701B (en) | 2010-10-27 | 2010-10-27 | Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105218283A CN102018701B (en) | 2010-10-27 | 2010-10-27 | Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018701A CN102018701A (en) | 2011-04-20 |
| CN102018701B true CN102018701B (en) | 2012-05-23 |
Family
ID=43860753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105218283A Expired - Fee Related CN102018701B (en) | 2010-10-27 | 2010-10-27 | Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018701B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730419B (en) * | 2021-10-08 | 2023-10-27 | 中国科学院昆明植物研究所 | 20S, 24R-epoxy-dammarane-3 beta, 12 beta, 25-triol derivative and pharmaceutical composition thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829100A (en) * | 2010-05-25 | 2010-09-15 | 大理学院 | Application of flavanonol lignanoid in preparing antiviral hepatitis B medicine |
-
2010
- 2010-10-27 CN CN2010105218283A patent/CN102018701B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829100A (en) * | 2010-05-25 | 2010-09-15 | 大理学院 | Application of flavanonol lignanoid in preparing antiviral hepatitis B medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018701A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2502703C (en) | A natural compound for prevention and treatment of diabetes, process for preparing the same, and pharmaceutical use thereof | |
| CN101966175A (en) | Application of dehydroabietic silybin in preparing glycosidase inhibitors | |
| CN102018701B (en) | Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors | |
| CN102000059B (en) | Medicinal application of querecetin dipolymer flavonoids to preparation of glycosidase enzyme inhibitors | |
| CN102000061B (en) | Medicinal application of nitrobenzoyl silybin in preparation of glycosidase inhibitor | |
| CN102000058B (en) | Application of B/E ring changed silybin in preparing glycosidase inhibitors | |
| CN102000057B (en) | Application of 4-cinnamoyl chloride substituted silybin in preparing glycosidase inhibitors | |
| CN102000064B (en) | Medicinal application of flavanonol lignan in preparation glycosidase inhibitors | |
| CN101966174B (en) | Pharmaceutical application of p-bromocinnamoyl silybin to preparing glycosidase inhibitors | |
| CN113004299B (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| CN102000063B (en) | Application of E ring benzyloxy substituted silybin in preparing glycosidase inhibitors | |
| CN102000056B (en) | Pharmaceutical application of B ring methoxy substituted silybin in preparing glycosidase inhibitors | |
| CN101966173B (en) | Medicinal use of dinitrobenzoylsilybin for preparing glycosidase inhibitor | |
| CN102000060B (en) | Application of E ring iodine substituted silybin to preparing glycosidase inhibitors | |
| CN102000062B (en) | Application of E ring bromine substituted silybin to preparing glycosidase inhibitors | |
| CN101829097A (en) | Application of dehydrogenation silybin in preparation of medicament for treating virus hepatitis B | |
| CN101590035B (en) | Application of dehydrogenated silybin in preparing anti-lung-cancer medicament | |
| CN106187973B (en) | The composition and preparation method and medical application of a kind of polyisocyanate chromocor derivative | |
| CN104083348A (en) | Applications of four kaurane diterpene compounds in preparation of glycosidase inhibitor medicines | |
| CN109575089B (en) | Acylated glucose compounds, pharmaceutical composition, preparation method and application thereof | |
| CN108530505A (en) | A kind of flavonoid glycoside compound and its preparation method and application | |
| CN101953828B (en) | Application of angle flavonoids lignan to preparation of medicaments for treating viral hepatitis B | |
| CN106431928B (en) | Caffeoylquinic acid derivative and application thereof as neuron repair and protection medicament | |
| CN104987340B (en) | Fluffy flavone A of alkali and its production and use | |
| CN116751179A (en) | New compound separated from white mulberry root-bark, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20131027 |